MTOR and cancer: Rapamycin analogues, such as temsirolimus (CCI-779) or everolimus (RAD-001) that target mTOR are now in different stages of clinical trials for anti-cancer therapy as a single agent [23] or as additive treatment having synergetic effect with ER- and HER2/neu- targeted therapy [24, 25].